A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE ...

Combined deletion of Fam134b and Fam134c in mice results in rapid axonal degeneration, highlighting the critical role of FAM134 proteins in preserving axonal architecture and function by controlling ...

Provided herein are novel lactams as SARM1 inhibitors, pharmaceutical compositions, use of such compounds in treating axonal degeneration and processes for preparing such compounds. Axonal ...

After injury, severed axons separated from their somas activate programmed axon degeneration, a conserved pathway to initiate their degeneration within a day. Conversely, severed projections deficient ...

While scientists have long known about axon degeneration, they haven’t had tools to stop it. Nura Bio’s lead drug candidate blocks a novel target associated with this damage to axons and the ...

Sironax Ltd. has discovered (+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetic neuropathy, multiple sclerosis, Parkinson ...

Summary: A new study explores the intricate relationship between myelin degeneration and neuron health. Contrary to the traditional view that demyelination primarily leads to axon degeneration, the ...

Here we show that TIR-1/dSarm/SARM1, a key regulator of axon degeneration, also inhibits regeneration of injured motor axons. The increased regeneration in tir-1 mutants is not a secondary consequence ...

Total tau (T-tau) protein has been considered to be another marker for axonal damage and neuronal degeneration in COVID-19 patients. Very few studies have found altered levels of plasma NfL among ...

SARM1 is also known to be involved in regulating innate immunity, potentially linking axon degeneration to the response to pathogens and intercellular signaling. Understanding this NAD-related ...

Accumulating evidence suggests that synaptic impairments and axonal degeneration precede neuronal cell body loss. Early synaptic changes may be a target to prevent disease onset and slow progression.

Eli Lilly and Company has acquired Disarm Therapeutics and its emerging therapies designed to prevent axonal degeneration in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), ...